HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Laxminarayan Bhat Selected Research

RP5063

10/2018A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.
5/2018Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
1/2018Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.
11/2017Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder.
9/2017RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
9/2017RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats.
1/2017RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Laxminarayan Bhat Research Topics

Disease

4Schizophrenia (Dementia Praecox)
10/2018 - 01/2017
3Psychotic Disorders (Schizoaffective Disorder)
10/2018 - 01/2017
3Pulmonary Arterial Hypertension
05/2018 - 09/2017
1Sleep Initiation and Maintenance Disorders (Insomnia)
11/2017
1Body Weight (Weight, Body)
11/2017
1Orthostatic Hypotension (Postural Hypotension)
11/2017
1Hypertrophy
09/2017
1Cognitive Dysfunction
01/2017

Drug/Important Bio-Agent (IBA)

7RP5063IBA
10/2018 - 01/2017
4Serotonin (5 Hydroxytryptamine)IBA
05/2018 - 09/2017
3Dopamine (Intropin)FDA LinkGeneric
05/2018 - 09/2017
3Serotonin ReceptorsIBA
05/2018 - 09/2017
2MonocrotalineIBA
05/2018 - 09/2017
1Sildenafil Citrate (Viagra)FDA Link
05/2018
1treprostinilFDA Link
05/2018
1Bosentan (Tracleer)FDA Link
05/2018
1Blood Glucose (Blood Sugar)IBA
11/2017
1LipidsIBA
11/2017
1ProlactinIBA
11/2017
1Antipsychotic Agents (Antipsychotics)IBA
01/2017

Therapy/Procedure

1Therapeutics
05/2018